Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis
William Damsky, Durga Thakral, Nkiruka Emeagwali, Anjela Galan, Brett King, William Damsky, Durga Thakral, Nkiruka Emeagwali, Anjela Galan, Brett King
Abstract
There is evidence that Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling plays a role in the pathogenesis of sarcoidosis. We treated a patient with cutaneous sarcoidosis with the JAK inhibitor tofacitinib; the patient had not previously had a response to medications and had not received systemic glucocorticoids. This treatment resulted in clinical and histologic remission of her skin disease. Sequencing of RNA and immunohistochemical examination of skin-lesion samples obtained from the patient before and during therapy and immunohistochemical testing of lesion samples obtained from other patients with cutaneous sarcoidosis support a role for JAK-STAT signaling in cutaneous sarcoidosis. (Funded by the Ranjini and Ajay Poddar Resource Fund for Dermatologic Diseases Research and others.).
Figures
Source: PubMed